Oclazid: Each tablet contains Gliclazide BP 80 mg.
Oclazid MR: Each modified release tablet contains Gliclazide BP 30 mg.
Oclazid & Oclazid MR are indicated for the treatment of type-2 (non-insulin dependent) diabetes when diet, exercise and weight loss have failed to control the blood sugar.
Gliclazide should not be used in Juvenile-onset (type-1) diabetes, diabetes associated with Ketosis, diabetic patients undergoing surgery; after severe injury or during infection, patients having hypersensitivity for sulfonylurea.
Dosage & Administration
Oclazid: The usual initial dose is to 1 tablet (40 to 80 mg) daily, gradually increasesed, if necessary, upto 4 tablet (320 mg). Doses of more than 160 mg daily are given in 2 divided doses.
Oclazid MR: The usual initial dose is 1 tablet (30 mg) once daily, gradually increased, if necessary, upto a maximum 4 tablets (120 mg) daily. It is recommended that the drug should be taken at breakfast time.
There are generally mild and infrequent side effects including hypoglycaemia, gastro-intestinal disturbances, headache, skin rashes etc.
Care should be exercised with patients having hepatic and or renal impairment and a small starting dose should be used with careful patient monitoring. In long term clinical trials, patients with renal insufficiency have been treated satisfactorily using Gliclazide at reduced doses
Certain drug as such as aspirin, antibacterial sulphonamides, beta-blockers, diazepam, tetracyclines, miconazole may increase the hypoglycaemic effect of Gliclazide. Oral contraceptives, rifampicin, barbiturates, corticosteroids may oppose the activity of gliclazide.
Oclazid: Box containing 5x10 tablets in blister strips.
Oclazid MR: Box containing 3x10 tablets in blister strips.